Serum CA125 level modifications in women undergoing repeated IVF cycles

In the present paper, serum CA125 modifications in patients undergoing their first IVF cycle were compared with those of patients in their second attempt. A significant increase of this marker was detected in each group of patients at day 14 after embryo transfer. However, the level of CA125 monitored in the patients in their second attempt was significantly higher than that determined in patients undergoing their first ovarian stimulation. This condition does not influence either ovarian response or oocyte and embryo quality. Moreover similar IVF outcome was obtained. Therefore we propose that patients undergoing repeated assisted reproductive technology (ART) cycles may suffer from ovarian surface epithelial damage and/or altered cellular growth rate.

Ovarian stimulation; CA125; IVF

[1] Duffy M.J.: "Clinical uses of tumor markers: a critical review". Crit. Rev. Clin. Lab. Sci., 2001, 38, 225.

[2] Caserta D., Marci R., Porzio G., Di Roma E., Moscarini M.: "Pelvic relapses in ovarian cancer. Role of CA125, transvaginal ultrasound and color Doppler". Eur. J. Gynaecol. Oncol., 2003, 24, 269.

[3] Zeimet A.G., Muller-Holzner E., Marth C., Daxenbichler G., Dapunt O.: "Tumor marker CA125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle". Fertil Steril., 1993, 59, 1028.

[4] Makrydimas G., Sotiriadis A., Paraskevaidis E., Pavlidis N., Agnantis N., Lolis D.: "Clear cell ovarian carcinoma in a pregnant woman with a history of infertility, endometriosis and unsuccessful IVF treatment". Eur. J. Gynaecol. Oncol., 2003, 24, 438.

[5] Urbancsek J., Hauzman E.E., Murber A., Lagarde A.R., Rabe T., Papp Z., Strowitzki T.: "Serum CA l25 and inhibin B levels in the prediction of ovarian response to gonadotropin stimulation in in vitro fertilization cycles". Gynecol. Endocrinol., 2005, 21, 38.

[6] Paoletti A.M., Serra G.G., Mais V., Ajossa S., Guerriero S., Orru M., Melis G.B.: "Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in CA125 occurring during the luteal phase and the first I 2 weeks of induced pregnancies". J. Assist. Re prod. Genet., 1995, 12, 263.

[7] Saraf V.K., O'Neill M., Riccioli A., Penha P.O., Obasaju M.F., Josimovich J.B.: "Correlations between periovulatory serum and follicular fluid CA-125 and granulosa cell hormones after controlled ovarian hyperstimulation". Eur. J. Obstet. Gynecol. Reprod. Biol., 1995, 62, 95.

[8] Tavmergen E., Sendag F., Goker E.N., Levi R.: "Value of serum CA 125 concentrations as predictors of pregnancy in assisted reproduction cycles". Hum. Reprod., 2001, 16, 1129.

[9] Van Steirteghem A.C., Nagy Z., Joris H., Liu J., Staessen C., Smitz J. et al.: "High fertilization and implantation rates after ICSI". Hum. Reprod., 1993 , 8, 1061.

[10] Staessen C., Camus M., Bollen N., Devroey P., Van Steirteghem A.C.: "The relationship between embryo quality and the occurrence of multiple pregnancies". Fertil. Steril., 1992, 57, 626.

[11] Brinton L.A., Moghissi K.S., Scoccia B., Westhoff C.L., Lamb E.J.: "Ovulation induction and cancer risk". Fertil. Steril., 2005, 83, 261.

[12] Shushan A., Laufer N.: "Fertility drugs and ovarian cancer: what are the practical implications of the ongoing debate?". Fertil. Steril., 2000, 74, 8.

[13] Rossing M.A., Daling J.R.: "Complexity of surveillance for cancer risk associated with in-vitro fertilisation". Lancet, 1999, 354, 1573.

[14] Phocas I., Sarandakou A., Rizos D., Dimitriadou F., Mantzavinos T., Zourlas P.A.: "Tumour-associated antigens, CEA, CA l25 and SCC in serum and follicular fluid of stimulated and unstimulated cycles". Eur. J. Obstet. Gynecol. Reprod. Biol., 1994, 54, 131.

[15] Sovino H., Sir-Petermann T., Devoto L.: "Clomiphene citrate and ovulation induction". Reprod. Biomed. Online, 2002, 4, 303.

[16] Murdoch W.J., Van Kirk E.A., Alexander B.M.: "DNA damages in ovarian surface epithelial cells of ovulatory hens". Exp. Biol. Med. (Maywood), 2005, 230, 429.

[17] Murdoch W.J.: "Metaplastic potential of p53 down-regulation in ovarian surface epithelial cells affected by ovulation" (letter). Cancer, 2003, 191, 75.

[18] Vujisic S., Kupesic S., Mihaljevic D., Aksamija A., Kurjak A.: "Evaluation of serum CA l25 concentration before and during hormonal induced cycles as predictor of IVF/ET outcome". Am. J. Reprod. lmmunol., 2002, 48, 355.

[19] Sohrabvand F., Bakhtiary M., Esfahani F., Jafarabadi M.: "Evaluation of prognostic value of CA125 serum levels in ICSI outcome". lnt. Congr. Ser., 2004, 1271, 81.

[20] Klip H., Burger C.W., Kenemans P., van Leeuwen F.E.: "Cancer risk associated with subfertility and ovulation induction: a review". Cancer Causes Control, 2000, 11, 319.